首页> 外国专利> METHOD FOR THE IMMOBILIZATION OF BIOACTIVE MOLECULES WITHIN A POLYMERIC SUBSTRATE RESISTANT TO THE STOMACH ACIDS AS ORAL DRUG DELIVERY SYSTEM

METHOD FOR THE IMMOBILIZATION OF BIOACTIVE MOLECULES WITHIN A POLYMERIC SUBSTRATE RESISTANT TO THE STOMACH ACIDS AS ORAL DRUG DELIVERY SYSTEM

机译:口服药物输送中抗肠胃酸的高分子底物中生物活性分子的固定化方法

摘要

It is described a technology which allows to surpass the gastric barrier for proteic compounds administrating bioactive molecules, particularly insulin. It is proposed a method to replace the daily repetitive injectable doses of insulin by a product oralyy administered. It is characterized by the following steps: a) mix at least a monomer suitable for polymerization by means of a ionizing radiation, with at least an aqueous solution of bioactive molecules; place the thus obtained mixture in step (a) into a resistant container permeable to said ionizing radiations; submit said container to a flow of ionizing radiation at a dose capable to polymerize all the monomer, in a dose range from 0.1 kGy up to 50 kGy, particularly in a 5 to 30 kGy in range, obtaining within the container a polymer resistant to the stomach acids. And the polymer containing in its nanotubules bioactive molecules; withdraw the thus polymer obtained in step (c), and dividing it in batches with a size range of 1 mm x 1 mm x 1 mm up to 8 mm x 8 mm x 8 mm, It is an objective of this invention. A method for the introduction of bioactive molecules in a polymeric substrate resistent to the stomach acids, to be employed as a retarding orally administered medicine, being these molecules insulin which is releaase directly to the liver being the liver its first action site, through the portal circulation; an orally relased insulin of delayed action by means of which, when the insulin is released into the liver, controls the porduction of hepatic glucose; an orally relased insulin of delayed action by means of which eht einsulin does not produce peaks in the systemic circulation, as it does with the injectable insulin, reducing the risks of the sudden descrese in the glucemia levels, an orally adminstered mediciene with a prolongued retared effect, by means of wish it is neccesary a lesser insulin dose.
机译:描述了一种技术,该技术可以使使用生物活性分子(特别是胰岛素)的蛋白质化合物超越胃屏障。提出了一种通过口服施用的产品代替每日重复注射胰岛素剂量的方法。其特征在于以下步骤:a)将至少适合于通过电离辐射聚合的单体与至少生物活性分子的水溶液混合;将步骤(a)中如此获得的混合物放入可透过所述电离辐射的抗性容器中;使所述容器以能够使所有单体聚合的剂量进行电离辐射流,剂量范围为0.1kGy至50kGy,特别是5至30kGy,从而在容器内获得对聚合物具有抗性的聚合物。胃酸。纳米管中含有生物活性分子的聚合物;取出在步骤(c)中得到的聚合物,将其以1mm×1mm×1mm的尺寸范围分成8mm×8mm×8mm的批次进行分割。一种将生物活性分子引入抵抗胃酸的聚合物底物中的方法,该方法被用作口服的延迟药物,这些分子是通过门直接向肝脏释放的胰岛素,它是肝脏的第一个作用部位循环;一种延迟释放的口服胰岛素,当胰岛素释放到肝脏中时,通过它控制肝葡萄糖的生成;口服延迟释放的胰岛素,通过这种途径,胰岛素不会像注射胰岛素那样在体循环中产生峰值,从而降低了血糖水平突然下降的风险,口服口服加有延缓药物作用的药物效果,希望有必要降低胰岛素剂量。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号